The Net Clinical Outcome of Dual-Pathway Inhibition in Clinical Practice: The "Xarelto plus Acetylsalicylic Acid: Treatment Patterns and Outcomes in Patients with Atherosclerosis" Registry

Conclusions: In the real-world XATOA registry, the annual rate of NCO events was low and numerically similar to those seen in the treatment group in the randomized COMPASS trial.PMID:38610724 | DOI:10.3390/jcm13071956

Source: Atherosclerosis - April 13, 2024 Category: Cardiology Authors: Alexander Breitenstein Alain Gay Kai Vogtl änder Keith A A Fox Jan Steffel XATOA Publication Committee Source Type: research